Memantine Hydrochloride

MEMANTINE HYDROCHLORIDE- memantine hydrochloride capsule, extended release
Par Pharmaceutical, Inc.

1 INDICATIONS AND USAGE

Memantine hydrochloride extended-release capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosing

The dosage of memantine hydrochloride extended-release capsules shown to be effective in a controlled clinical trial is 28 mg once daily.

The recommended starting dose of memantine hydrochloride extended-release capsules is 7 mg once daily. The dose should be increased in 7 mg increments to the recommended maintenance dose of 28 mg once daily. The minimum recommended interval between dose increases is one week. The dose should only be increased if the previous dose has been well tolerated. The maximum recommended dose is 28 mg once daily.

Memantine hydrochloride extended-release capsules can be taken with or without food. Memantine hydrochloride extended-release capsules can be taken intact or may be opened, sprinkled on applesauce, and thereby swallowed. The entire contents of each memantine hydrochloride extended-release capsule should be consumed; the dose should not be divided.

Except when opened and sprinkled on applesauce, as described above, memantine hydrochloride extended-release capsules should be swallowed whole. Memantine hydrochloride extended-release capsules should not be divided, chewed, or crushed.

If a patient misses a single dose of memantine hydrochloride extended-release capsules, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to take memantine hydrochloride extended-release capsules for several days, dosing may need to be resumed at lower doses and retitrated as described above.

2.2 Switching from Memantine Hydrochloride Immediate-Release Tablets to Memantine Hydrochloride Extended-Release Capsules

Patients treated with memantine hydrochloride immediate-release tablets may be switched to memantine hydrochloride extended-release capsules as follows:

It is recommended that a patient who is on a regimen of 10 mg twice daily of memantine hydrochloride immediate-release tablets be switched to memantine hydrochloride extended-release capsules 28 mg once daily capsules the day following the last dose of 10 mg memantine hydrochloride immediate-release tablets. There is no study addressing the comparative efficacy of these 2 regimens.

In a patient with severe renal impairment, it is recommended that a patient who is on a regimen of 5 mg twice daily of memantine hydrochloride immediate-release tablets be switched to memantine hydrochloride extended-release capsules 14 mg once daily capsules the day following the last dose of 5 mg memantine hydrochloride immediate-release tablets.

2.3 Dosing in Patients with Renal Impairment

In patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min, based on the Cockcroft-Gault equation), the recommended maintenance dose (and maximum recommended dose) is 14 mg/day [ see Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS

Each capsule contains 7 mg, 14 mg, 21 mg, or 28 mg of memantine HCl.

  • The 7 mg, capsule is a Size 4CS hard gelatin capsule with yellow opaque cap and yellow opaque body, imprinted with “par” on the cap and “C346” on the body in black ink, containing white to off-white spherical-shaped film-coated pellets.
  • The 14 mg, capsule is a Size 4CS hard gelatin capsule with green opaque cap and yellow opaque body, imprinted with “par” on the cap and “C347” on the body in black ink, containing white to off-white spherical-shaped film-coated pellets.
  • The 21 mg, capsule is a Size 3CS hard gelatin capsule with green opaque cap and white opaque body, imprinted with “par” on the cap and “C348” on the body in black ink, containing white to off-white spherical-shaped film-coated pellets.
  • The 28 mg, capsule is a Size 2CS hard gelatin capsule with green opaque cap and green opaque body, imprinted with “par” on the cap and “C349” on the body in black ink, containing white to off-white spherical-shaped film-coated pellets.

4 CONTRAINDICATIONS

Memantine hydrochloride extended-release capsules are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

5 WARNINGS AND PRECAUTIONS

5.1 Genitourinary Conditions

Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine [ see Drug Interactions (7.1)].

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Memantine hydrochloride extended-release capsules were evaluated in a double-blind placebo-controlled trial in which a total of 676 patients with moderate to severe dementia of the Alzheimer’s type (341 patients on Memantine hydrochloride extended-release capsules 28 mg/day and 335 patients on placebo) were treated for up to 24 weeks.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions Leading to Discontinuation

In the placebo-controlled clinical trial of memantine hydrochloride extended-release capsules, the proportion of patients in the memantine hydrochloride extended-release capsules group and the placebo group who discontinued treatment due to adverse reactions was 10% and 6%, respectively. The most common adverse reaction that led to treatment discontinuation in the memantine hydrochloride extended-release capsules group was dizziness, at a rate of 1.5%.

Most Common Adverse Reactions

The most commonly observed adverse reactions seen in patients administered memantine hydrochloride extended-release capsules in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the memantine hydrochloride extended-release capsules group and at a frequency higher than placebo, were headache, diarrhea and dizziness.

Table 1 lists adverse reactions that were observed at an incidence of ≥ 2% in the memantine hydrochloride extended-release capsules group and occurred at a rate greater than placebo.

Table 1: Adverse reactions observed with a frequency of ≥ 2% in the Memantine Hydrochloride Extended-Release Capsules group and at a rate greater than placebo

Adverse reaction

Placebo(n = 335)%

Memantine Hydrochloride Extended-Release Capsules 28 mg(n = 341)%

Gastrointestinal Disorders

Diarrhea

4

5

Constipation

1

3

Abdominal pain

1

2

Vomiting

1

2

Infections and infestations

Influenza

3

4

Investigations

Weight, increased

1

3

Musculoskeletal and connective tissue disorders

Back pain

1

3

Nervous system disorders

Headache

5

6

Dizziness

1

5

Somnolence

1

3

Psychiatric disorders

Anxiety

3

4

Depression

1

3

Aggression

1

2

Renal and urinary disorders

Urinary incontinence

1

2

Vascular disorders

Hypertension

2

4

Hypotension

1

2

Seizure

Memantine has not been systematically evaluated in patients with a seizure disorder. In clinical trials of memantine, seizures occurred in 0.3% of patients treated with memantine and 0.6% of patients treated with placebo.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.